Proteome Systems Licenses Eukarion Compounds to Minerva, Names New CEO | GenomeWeb
NEW YORK (GenomeWeb News) — Proteome Systems has licensed its Eukarion portfolio of small-molecule drug compounds to Minerva Healthcare, which is developing treatments for dermatological and other diseases, Proteome Systems said last week. 
The company also said it has appointed Jenny Harry CEO, replacing Stephen Porges. Harry has been deputy CEO since 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.